Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's defendants provided misleading information regarding the expected results of their Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that while setrusumab increases bone density, it does not correlate with a decrease in fracture rates, contrary to the positive statements made by the defendants [6].

New York, New York--(Newsfile Corp. - February 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conting ...

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding the efficacy of its drug setrusumab for treating Osteogenesis Imperfecta [1][1][1] Summary by Relevant Sections Class Action Details - Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, can seek to be lead plaintiffs in the class action lawsuit, which is titled Bailey v. Ultragenyx Pharmaceutical Inc. [1][1] - The lawsuit alleges that Ultragenyx and its executives made false statements about the reliability of data from the Phase III Orbit study, which was intended to show the drug's effectiveness [1][1] Allegations Against Ultragenyx - The lawsuit claims that Ultragenyx created a misleading impression of having reliable information regarding the effects of setrusumab while downplaying the risks associated with the Phase III Orbit study [1][1] - It is alleged that the company failed to disclose that the Phase II results lacked a placebo control group, which could have influenced the perceived effectiveness of the treatment [1][1] Stock Price Impact - Following the announcement on July 9, 2025, that the Phase III Orbit study did not achieve statistical significance, Ultragenyx's stock price fell by more than 25% [1][1] - On December 29, 2025, after revealing that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, the stock price dropped by over 42% [1][1] Legal Process for Lead Plaintiffs - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Ultragenyx common stock during the class period to seek appointment as lead plaintiff, representing the interests of all class members [1][1] - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [1][1] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1][1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [1][1]

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab for treating Osteogenesis Imperfecta [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Bailey v. Ultragenyx Pharmaceutical Inc., and it includes purchasers of Ultragenyx common stock from August 3, 2023, to December 26, 2025 [1]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff in the lawsuit [1][6]. - The lawsuit alleges that Ultragenyx misrepresented the reliability of data from its Phase III Orbit study, which failed to show a statistically significant reduction in annualized fracture rate [3]. Group 2: Allegations and Stock Impact - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance, leading to a stock price drop of over 25% [4]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [5]. - The company attributed the study failures to a low fracture rate in the placebo group and a trend that did not reach statistical significance [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Ultragenyx stock during the class period to seek lead plaintiff status [6]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [7].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the efficacy of its drug setrusumab during the specified class period [2][4][7]. Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [2][7]. - The complaint alleges that Ultragenyx made false statements about the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients and downplayed risks associated with clinical trial results [4][7]. - Investors have until April 6, 2026, to file for lead plaintiff status in the lawsuit [2][9]. Group 2: Stock Performance - On December 29, 2025, Ultragenyx's stock price dropped over 42%, falling from $34.19 per share to $19.72 per share after the company announced that its Phase III studies did not achieve statistical significance [5][7]. Group 3: Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to discuss their legal rights [3][10]. - Options for investors include filing to be a lead plaintiff by the deadline or choosing to remain an absent class member [9].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - February ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Ultragenyx a ...

Philadelphia, Pennsylvania--(Newsfile Corp. - February 24, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2023 through December 26, 2025 (the "Class Period").Investor Deadline: Investors who purchased Ultragenyx securities during the Class Period may, no later than Ap ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...